Chemomab Therapeutics Ltd. CMMB
1.18 USD 0.00 (-0.42%)
Nov 3, 2026, 1:52 PM EST
1.16 Day range 1.33
0.92 52-week range 2.99
- YTD
- -28.79%
- 1 year
- -58.04%
Analyst view
Price target (mean) 8.00 +580.9% upside
Now 1.18
- Target (low)
- 4.00
- Target (mean)
- 8.00
- Target (high)
- 11.00
Ratings (0m) 3 3 buy · 0 hold · 0 sell
- Strong buy2
- Buy1
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 3
- 1 month ago 3
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.01 | -0.01 – -0.01 | -0.013 | +23.1% | 0 | 0.0% | 2 |
| Next quarter | -0.01 | -0.01 – -0.01 | -0.014 | +28.6% | 0 | 0.0% | 2 |
| Current year | -0.05 | -0.05 – -0.05 | -0.103 | +51.5% | 0 | 0.0% | 2 |
| Next year | -0.035 | -0.04 – -0.03 | -0.05 | +30.0% | 0 | 0.0% | 2 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 15, 2024 | Oppenheimer | Reiterated | Outperform | Outperform |
| May 13, 2024 | Maxim Group | Initiated | — | Buy |
| May 6, 2024 | Oppenheimer | Upgrade | Perform | Outperform |
| Mar 8, 2024 | Oppenheimer | Maintained | Perform | Perform |
| Oct 6, 2023 | Roth MKM | Initiated | — | Buy |
| Jun 7, 2023 | Oppenheimer | Downgrade | Outperform | Perform |
| Apr 18, 2023 | Oppenheimer | Maintained | — | Outperform |
| Mar 10, 2022 | Oppenheimer | Maintained | — | Outperform |
| Dec 7, 2021 | Aegis Capital | Initiated | — | Buy |
| May 26, 2021 | Cantor Fitzgerald | Initiated | — | Overweight |
| May 7, 2021 | Oppenheimer | Initiated | — | Outperform |